We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.35B
AUM Growth
+$25.5M
Cap. Flow
+$32.7M
Cap. Flow %
2.42%
Top 10 Hldgs %
12.05%
Holding
2,121
New
584
Increased
441
Reduced
528
Closed
563

Top Sells

Rank Stock Value
1
LMND icon
Lemonade
LMND
+$4.64M
2
MGNI icon
Magnite
MGNI
+$3.66M
3
RELY icon
Remitly
RELY
+$3.66M
4
MNRO icon
Monro
MNRO
+$3.65M
5
VGR
Vector Group Ltd.
VGR
+$3.32M

Sector Composition

Rank Sector Weight
1 Technology 16.19%
2 Healthcare 13.13%
3 Financials 12.64%
4 Consumer Discretionary 12.16%
5 Industrials 9.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DDD icon
1526
3D Systems Corp
DDD
$613M
$61K ﹤0.01%
+18,467
New +$58.9K
IRWD icon
1527
Ironwood Pharmaceuticals
IRWD
$714M
$61K ﹤0.01%
13,867
-337,326
-96% -$1.37M
HBIO icon
1528
Harvard Bioscience
HBIO
$29.2M
$60K ﹤0.01%
2,821
+1,716
+155% +$39.4K
RMTI icon
1529
Rockwell Medical
RMTI
$28.2M
$58K ﹤0.01%
2,835
-6,024
-68% -$176K
AILE
1530
DELISTED
iLearningEngines, Inc. Common Stock
AILE
$58K ﹤0.01%
+137,443
New +$176K
QS icon
1531
QuantumScape Corp
QS
$3.74B
$56K ﹤0.01%
+10,748
New +$56.4K
SNDL icon
1532
Sundial Growers
SNDL
$320M
$56K ﹤0.01%
+31,313
New +$61.4K
NVTS icon
1533
Navitas Semiconductor
NVTS
$3.63B
$55K ﹤0.01%
15,504
-2,356
-13% -$6.55K
ASRT
1534
DELISTED
Assertio
ASRT
$54K ﹤0.01%
4,131
-5,867
-59% -$87.4K
TTI icon
1535
TETRA Technologies
TTI
$1.26B
$52K ﹤0.01%
+14,617
New +$51.9K
OXLC
1536
Oxford Lane Capital
OXLC
$898M
$51K ﹤0.01%
+2,003
New +$52.5K
VOC icon
1537
VOC Energy
VOC
$51.9M
$48K ﹤0.01%
+10,103
New +$50.6K
VLN icon
1538
Valens Semiconductor
VLN
$188M
$46K ﹤0.01%
+17,838
New +$35.7K
PRME icon
1539
Prime Medicine
PRME
$559M
$45K ﹤0.01%
15,311
-83,749
-85% -$294K
APLT
1540
DELISTED
Applied Therapeutics
APLT
$44K ﹤0.01%
+50,994
New +$320K
AMLX icon
1541
Amylyx Pharmaceuticals
AMLX
$2.54B
$40K ﹤0.01%
+10,639
New +$50.1K
CTMX icon
1542
CytomX Therapeutics
CTMX
$754M
$40K ﹤0.01%
+38,885
New +$41.8K
IPM
1543
Intelligent Protection Management Corp
IPM
$24.1M
$40K ﹤0.01%
20,000
ANGI icon
1544
Angi Inc
ANGI
$196M
$38K ﹤0.01%
+2,304
New +$49.1K
HYLN icon
1545
Hyliion Holdings
HYLN
$690M
$32K ﹤0.01%
+12,075
New +$33.6K
SGMO
1546
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$32K ﹤0.01%
31,553
-314,079
-91% -$574K
BTE icon
1547
Baytex Energy
BTE
$2.92B
$31K ﹤0.01%
+11,900
New +$33.8K
CVGI icon
1548
Commercial Vehicle Group
CVGI
$147M
$31K ﹤0.01%
+12,403
New +$33.1K
KNDI
1549
Kandi Technologies Group
KNDI
$65.5M
$30K ﹤0.01%
+24,687
New +$32.1K
CNTX icon
1550
Context Therapeutics
CNTX
$44.5M
$28K ﹤0.01%
+27,122
New +$46.9K

Similar funds

GSA Capital Partners's Q4 2024 Portfolio in Review

As of Q4 2024, GSA Capital Partners held 2,121 positions worth $1.35B, up 1.9% from $1.32B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

GSA Capital Partners's Q4 2024 filing shows 584 new, 441 increased, 528 reduced and 563 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 165,180 shares worth $97.2M. The largest sale was Lemonade, an estimated $4.64M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Healthcare and Financials.

  • GSA Capital Partners's largest Q4 2024 buy was iShares Core S&P 500 ETF: 165,180 shares worth $97.2M.
  • GSA Capital Partners added most to Frontline in Q4 2024, an estimated $5.7M increase.
  • GSA Capital Partners's biggest Q4 2024 reduction was Lemonade, cutting an estimated $4.64M.
  • GSA Capital Partners fully exited Monro in Q4 2024, selling an estimated $3.65M.
  • GSA Capital Partners's ten largest holdings make up 12% of its $1.35B portfolio in Q4 2024.
  • GSA Capital Partners opened 584 new positions and closed 563 in Q4 2024.
  • GSA Capital Partners's portfolio value rose 1.9% quarter-over-quarter to $1.35B.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.